• Something wrong with this record ?

Unlocking the potential: FKK6 as a microbial mimicry-based therapy for chronic inflammation-associated colorectal cancer in a murine model

L. Sládeková, H. Li, VM. DesMarais, AP. Beck, H. Guzik, B. Vyhlídalová, H. Gu, S. Mani, Z. Dvořák

. 2025 ; 392 (2) : 100059. [pub] 20241210

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25009971

Chronic intestinal inflammation significantly contributes to the development of colorectal cancer and remains a pertinent clinical challenge, necessitating novel therapeutic approaches. Indole-based microbial metabolite mimics Felix Kopp Kortagere 6 (FKK6), which is a ligand and agonist of the pregnane X receptor (PXR), was recently demonstrated to have PXR-dependent anti-inflammatory and protective effects in a mouse model of dextran sodium sulfate (DSS)-induced acute colitis. Here, we examined the therapeutic potential of FKK6 in a mouse model (C57BL/6 FVB humanized PXR mice) of colitis-associated colon cancer (CAC) induced by azoxymethane and DSS. FKK6 (2 mg/kg) displayed substantial antitumor activity, as revealed by reduced size and number of colon tumors, improved colon histopathology, and decreased expression of tumor markers (c-MYC, β-catenin, Ki-67, and cyclin D) in the colon. In addition, we carried out a chronic toxicity (30 days) assessment of FKK6 (1 mg/kg and 2 mg/kg) in C57BL/6 mice. Histological examination of tissues, biochemical blood analyses, and immunohistochemical staining for Ki-67 and γ-H2AX showed no difference between FKK6-treated and control mice. Comparative metabolomic analyses in mice exposed for 5 days to DSS and administered with FKK6 (0.4 mg/kg) revealed no significant effects on several classes of metabolites in the mouse fecal metabolome. Ames and micronucleus tests showed no genotoxic and mutagenic potential of FKK6 in vitro. In conclusion, anticancer effects of FKK6 in azoxymethane/DSS-induced CAC, together with FKK6 safety data from in vitro tests and in vivo chronic toxicity study, and comparative metabolomic study, are supportive of the potential therapeutic use of FKK6 in the treatment of CAC. SIGNIFICANCE STATEMENT: Microbial metabolite mimicry proposes that chemical mimics of microbial metabolites that serve to protect hosts against aberrant inflammation in the gut could serve as a new paradigm for the development of drugs targeting inflammatory bowel disease if, like the parent metabolite, is devoid of toxicity but more potent against the microbial metabolite receptor. We identified a chemical mimic of Felix Kopp Kortagere 6, and we propose that Felix Kopp Kortagere 6 is devoid of toxicity yet significantly reduces tumor formation in an azoxymethane-dextran sodium sulfate model of murine colitis-induced colon cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009971
003      
CZ-PrNML
005      
20250429134718.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpet.2024.100059 $2 doi
035    __
$a (PubMed)40023602
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sládeková, Lucia $u Department of Cell Biology and Genetics, Faculty of Science, Palacký University, Olomouc, Czech Republic
245    10
$a Unlocking the potential: FKK6 as a microbial mimicry-based therapy for chronic inflammation-associated colorectal cancer in a murine model / $c L. Sládeková, H. Li, VM. DesMarais, AP. Beck, H. Guzik, B. Vyhlídalová, H. Gu, S. Mani, Z. Dvořák
520    9_
$a Chronic intestinal inflammation significantly contributes to the development of colorectal cancer and remains a pertinent clinical challenge, necessitating novel therapeutic approaches. Indole-based microbial metabolite mimics Felix Kopp Kortagere 6 (FKK6), which is a ligand and agonist of the pregnane X receptor (PXR), was recently demonstrated to have PXR-dependent anti-inflammatory and protective effects in a mouse model of dextran sodium sulfate (DSS)-induced acute colitis. Here, we examined the therapeutic potential of FKK6 in a mouse model (C57BL/6 FVB humanized PXR mice) of colitis-associated colon cancer (CAC) induced by azoxymethane and DSS. FKK6 (2 mg/kg) displayed substantial antitumor activity, as revealed by reduced size and number of colon tumors, improved colon histopathology, and decreased expression of tumor markers (c-MYC, β-catenin, Ki-67, and cyclin D) in the colon. In addition, we carried out a chronic toxicity (30 days) assessment of FKK6 (1 mg/kg and 2 mg/kg) in C57BL/6 mice. Histological examination of tissues, biochemical blood analyses, and immunohistochemical staining for Ki-67 and γ-H2AX showed no difference between FKK6-treated and control mice. Comparative metabolomic analyses in mice exposed for 5 days to DSS and administered with FKK6 (0.4 mg/kg) revealed no significant effects on several classes of metabolites in the mouse fecal metabolome. Ames and micronucleus tests showed no genotoxic and mutagenic potential of FKK6 in vitro. In conclusion, anticancer effects of FKK6 in azoxymethane/DSS-induced CAC, together with FKK6 safety data from in vitro tests and in vivo chronic toxicity study, and comparative metabolomic study, are supportive of the potential therapeutic use of FKK6 in the treatment of CAC. SIGNIFICANCE STATEMENT: Microbial metabolite mimicry proposes that chemical mimics of microbial metabolites that serve to protect hosts against aberrant inflammation in the gut could serve as a new paradigm for the development of drugs targeting inflammatory bowel disease if, like the parent metabolite, is devoid of toxicity but more potent against the microbial metabolite receptor. We identified a chemical mimic of Felix Kopp Kortagere 6, and we propose that Felix Kopp Kortagere 6 is devoid of toxicity yet significantly reduces tumor formation in an azoxymethane-dextran sodium sulfate model of murine colitis-induced colon cancer.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a myši inbrední C57BL $7 D008810
650    12
$a modely nemocí na zvířatech $7 D004195
650    12
$a kolorektální nádory $x farmakoterapie $x metabolismus $x patologie $7 D015179
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a síran dextranu $x toxicita $7 D016264
650    _2
$a zánět $x farmakoterapie $x metabolismus $7 D007249
650    _2
$a azoxymethan $x toxicita $7 D001397
650    _2
$a indoly $x farmakologie $x terapeutické užití $7 D007211
650    _2
$a kolitida $x farmakoterapie $x chemicky indukované $x metabolismus $x patologie $7 D003092
650    _2
$a nádory asociované s kolitidou $x patologie $x farmakoterapie $x metabolismus $7 D000083023
650    _2
$a molekulární mimikry $7 D018716
650    _2
$a chronická nemoc $7 D002908
650    _2
$a ženské pohlaví $7 D005260
655    _2
$a časopisecké články $7 D016428
700    1_
$a Li, Hao $u Department of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York
700    1_
$a DesMarais, Vera M $u Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York; Analytical Imaging Facility, Albert Einstein College of Medicine, Bronx, New York
700    1_
$a Beck, Amanda P $u Department of Pathology, Albert Einstein College of Medicine, Bronx, New York
700    1_
$a Guzik, Hillary $u Analytical Imaging Facility, Albert Einstein College of Medicine, Bronx, New York
700    1_
$a Vyhlídalová, Barbora $u Department of Cell Biology and Genetics, Faculty of Science, Palacký University, Olomouc, Czech Republic
700    1_
$a Gu, Haiwei $u Arizona Metabolomics Laboratory, College of Health Solutions, Arizona State University, Phoenix, Arizona
700    1_
$a Mani, Sridhar $u Department of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York
700    1_
$a Dvořák, Zdenek $u Department of Cell Biology and Genetics, Faculty of Science, Palacký University, Olomouc, Czech Republic. Electronic address: zdenek.dvorak@upol.cz
773    0_
$w MED00002900 $t The Journal of pharmacology and experimental therapeutics $x 1521-0103 $g Roč. 392, č. 2 (2025), s. 100059
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40023602 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134713 $b ABA008
999    __
$a ok $b bmc $g 2311379 $s 1247052
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 392 $c 2 $d 100059 $e 20241210 $i 1521-0103 $m The Journal of pharmacology and experimental therapeutics $n J Pharmacol Exp Ther $x MED00002900
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options